Navigation Links
3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
Date:1/8/2010

SHENYANG, China, Jan. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use. Feraheme is an intravenous iron therapy that 3SBio licensed from AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for development in China for the treatment of iron deficiency anemia in adult patients with chronic kidney disease ("CKD").

Feraheme was approved on June 30, 2009 by the U.S. Food and Drug Administration for the same indication for which 3SBio is seeking approval in China and launched commercially in the U.S. by AMAG in July 2009. As previously announced, 3SBio has exclusive rights to develop and commercialize Feraheme in China. Once approved by the SFDA, 3SBio will commence a multi-center randomized efficacy and safety study in China with approximately 200 CKD patients, measuring the mean change in hemoglobin from baseline at Day 35 after first dose.

Dr. Jing Lou, Chief Executive Officer of 3SBio comments: "We are pleased with the timely submission of the Feraheme clinical trial application to the SFDA in China, representing a major milestone and our commitment to bringing this innovative therapy to Chinese CKD patients in need. We look forward to working with the SFDA to ensure an efficient review process."

Brian J.G. Pereira, MD, President and Chief Executive Officer of AMAG Pharmaceuticals comments: "3SBio is the ideal partner to bring Fer
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
2. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
3. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
4. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
5. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
6. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
7. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
8. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
9. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. Files for SFDA Approval of NuLeusin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Texas (PRWEB) , ... July ... ... biotechnology company providing industry-leading products for use in applications such as animal ... in wastewater treatment plants and restaurant kitchen settings, announced today that it ...
(Date:7/3/2015)... , July 3, 2015 ... 22 september 2015 på  http://www.openinnovationinscience.at till ... in Science" som hålls i ... färsk undersökning med internationella forskare och vetenskapsmän ... är hälsovetenskapens två största utmaningar bristen på ...
(Date:7/2/2015)... ... ... been used in countless labs for decades. In the past, people had to go ... this was a daunting and tiring process looking at endless data tables and charts. ... the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away those old ...
(Date:7/2/2015)... ... , ... Sleepless nights will become obsolete as Luzi , a sophisticated ... on June 23. Sound sleepers and the sleep deprived both will love Luzi for ... the integration of the Bluetooth speaker, alarm clock and ability to charge various devices, ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3
... Large Well-Known Product and Continues ... of Antibody Therapeutics Pipeline -, BRITISH COLUMBIA, Canada, ... TSX Venture: IXS;, http://www.ixsbio.com ), a drug development company ... Dynamic Cross Linking,(DXL(TM)) technology, announces the development of a ...
... reported results for the quarter ended September 30, 2008.,Revenue ... to $112,000 for,the quarter ended September 30, 2007. Revenue ... compared to $715,000 for the nine months,ended September 30, ... quarter of 2008 were,$17.3 million compared to $19.8 million ...
... Residual Vascular Risk Reduction: The Global Call to Action, ... Initiative:,R3i, KEY FACTS:, Residual Risk Reduction Initiative (R3i) ... unaddressed by current standards of,care in millions of patients with ... Audubon Room, Ritz Carlton Hotel, 921 Canal Street, New Orleans, ...
Cached Biology Technology:InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 2InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 3Dendreon Reports Third Quarter 2008 Financial Results 2Dendreon Reports Third Quarter 2008 Financial Results 3Dendreon Reports Third Quarter 2008 Financial Results 4Dendreon Reports Third Quarter 2008 Financial Results 5
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... German . Much celebration at the ... has approved funding for a long-term research project by Professors ... and Dr. Frank Spinath from Saarland University. They are studying ... 4,000 pairs of twins living in Germany. The name of ...
... to a new study from the Slone Epidemiology Center (SEC) ... age 11 had a greater likelihood of adult-onset asthma compared ... The study, which is published online in ... led by Patricia Coogan, DSc, senior epidemiologist at SEC and ...
... discovered by a Northwestern University professor and now tested ... been shown to alleviate symptoms within hours, have good ... seven days from a single dose. The ... memory -- a very different approach from existing antidepressants. ...
Cached Biology News:German Research Foundation to fund globally unique twin study on social inequality 2Abuse during childhood linked to adult-onset asthma in African-American women 2New antidepressant acts very rapidly and is long lasting 2New antidepressant acts very rapidly and is long lasting 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: